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all patients) failed initially in the CNS.
Four additional patients subsequently
developed CNS metastases, for an over-
all CNS failure rate of 12 of 20 (relaps-
ing) patients, or 60%, representing al-
most 50% of all well-staged stage IIIA
and B NSCLC patients failing in the
CNS. (These failures were detected clin-
ically because routine post-study mag-
netic resonance imaging was not per-
formed). Thus, we hypothesize that the
low incidence of 8% CNS metastasis in
the Choong et al. study might in fact
suggest that temozolomide could poten-
tially have controlled microscopic CNS
disease in a proportion of patients.
Consistent with this supposition,
an earlier study reported by Adonizio et
al.3 using temozolomide as a single
agent produced similar results: five of
38 patients entered the study with
treated brain metastasis; two had CNS
progression and only one patient devel-
oped brain metastasis on study for an
incidence of 3%.
These results, taken collectively,
provide putative support for a well-
structured prospective clinical trial to
test the value of temozolomide for “pro-
phylaxis” (i.e., in reality, the treatment
of micrometastatic disease) of the CNS
in NSCLC. Such a study is now in its
final stages of development as a joint
project between the University of Wis-
consin Comprehensive Cancer Center,
the University of Texas Southwestern
Cancer Center, Dallas (Dr. Joan
Schiller), and the Fox Chase Cancer
Center, Philadelphia (Dr. Cory Langer).
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Reply to the Letter by
Robins et al.
To the Editor:
On behalf of the coauthors, we are
replying to the letter by Dr. Robins and
colleagues.
In our study evaluating temozolo-
mide and irinotecan as second-line
agents, we determined that the response
rate was only 9% with a short median
time to progression of 1.8 months. As a
result, the duration of treatment was
short (median two cycles or 6 weeks). In
this brief period, 67% of our subjects
had progressive disease including three
patients who developed new symptom-
atic brain metastasis. Because brain im-
aging was not required post-study, the
incidence of asymptomatic brain metas-
tasis is unknown but probably higher
than 8%.1 In addition, our trial was not
designed to specifically address the ef-
fect of temozolomide on brain metasta-
sis. We agree that the role of temozolo-
mide as prophylaxis against central
nervous system metastasis should be
evaluated in a large, well-designed pro-
spective trial.
Thank you very much for allow-
ing us to reply.
Nicholas W. Choong MD, and
Everett E. Vokes, MD
Section of Hematology-Oncology
University of Chicago Medical Center,
Chicago, Illinois
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Efficacy of Gefitinib in a
Patient with Lung
Cancer Associated with
Idiopathic Pulmonary
Fibrosis
To the Editor:
Lung cancer frequently develops
in patients with idiopathic pulmonary
fibrosis (IPF).1 However, there is no
established or standardized chemother-
apy to date for advanced lung cancer
associated with IPF. Gefitinib, an oral
inhibitor of epidermal growth factor re-
ceptor (EGFR) tyrosine kinase domain,
is effective for selected patients with
advanced non-small cell lung cancer
(NSCLC).2 However, the incidence of
interstitial lung disease (ILD) caused by
gefitinib is as high as 5% in Japan, and
preexisting pulmonary fibrosis is con-
sidered to be a risk factor for developing
ILD.3,4 We report the case of a patient
with stage IV adenocarcinoma associ-
ated with IPF who was successfully
treated with gefitinib.
A 77-year-old man was admitted
to our hospital for the evaluation of a
mass lesion on chest radiograph. He
had smoked one pack of cigarettes
daily for 59 years. On examination,
fine crackles were heard at both lung
bases. A chest computed tomography
(CT) scan revealed a lobulated mass,
66  50 mm in diameter, in the right
upper lobe with enlargement of para-
tracheal, pretracheal, and subcarinal
lymph nodes (Figure 1A). In addition,
honeycombing was observed in the
lung base bilaterally (Figure 1B). A
diagnosis of adenocarcinoma was
made by transbronchial biopsy. Brain
CT disclosed a metastatic lesion, 5
mm in diameter, in the right parietal
lobe. The patient was diagnosed as
having stage IV (cT2N2M1) NSCLC
associated with IPF. At first, the brain
metastasis was treated by stereotactic
radiosurgery (gamma knife). Subse-
quently, the patient preferred gefitinib
for the first-line therapy to intravenous
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